THE ACADEMIC CONSORTIUM
The ReIMAGINE consortium comprises many of the world’s globally pre-eminent thought leaders in the area of prostate cancer diagnosis (Ahmed, Moore, and Emberton), imaging (Punwani), molecular characterisation (Attard and Whitaker), clinical epidemiology (Van Hemelrijck), advanced analytics (Coolen) and statistics (Brown), and global consortia/consensus development (Moore).
PROFESSOR MARK EMBERTON
Professor of Interventional Oncology at UCL. Mark will lead WS7, project management/commercial. Project Management (PM) will be informed at every stage by real-time inputs. All work strands will be advanced & coordinated by means of our PM system that will also serve our numerous commercial partners.
PROFESSOR HASHIM AHMED
Academic urologist with an interest in improving diagnosis and treatment options for men with prostate cancer through translational studies, health technology assessment and clinical trials.
ReIMAGINE 'Risk' Co-Chief Investigator
PROFESSOR SHONIT PUNWANI
Professor of Magnetic Resonance and Cancer Imaging and Consultant Radiologist at UCLH Shonit will lead on WS3. Curation and post-processing of the imaging (MRI) data will be managed through WS3.
PROFESSOR GERHARDT ATTARD
A John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. Gert will lead WS4, which will manage genomic, transcriptomic, epigenetic, immune/inflammatory data from tumour cores, blood and urine.
Professor MIEKE VAN HEMELRIJCK
Mieke is leading the database management of the ReIMAGINE Consortium as well as the patient and public involvement (WS5 and WS6). Mieke is an expert in clinical epidemiology, specifically in the context of big data for urological cancers.
PROFESSOR ANTHONY COOLEN
Applied mathematician with an interest in the development and application of advanced mathematical and statistical methods for predicting cancer outcomes and treatment response from complex data. Ton is the Co-lead for WS5.
PROFESSOR CAROLINE MOORE
Professor of Urology at UCL is leading the screening study of ReIMAGINE seeking to determine the utility of MRI in men, identified via their GP practice, who have never had a PSA test. Caroline is working with experts in cancer screening and imaging in ReIMAGINE.
ReIMAGINE 'Screening' Co-Chief Investigator
DR HALEY WHITAKER
Reader in Cancer Biology at UCL, with expertise in prostate cancer biomarker development and validation
DR LOUISE BROWN
A Senior Statistician at the MRC Clinical Trials Unit at University College London, who will be working on the statistical aspects of REIMAGINE.